申请人:Harbeson Scott L.
公开号:US20080262006A1
公开(公告)日:2008-10-23
This invention relates to novel endothelin receptor antagonists that selectively inhibit the interaction between Endothelin-1 (ET-1) and endothelin type-A receptors, their derivatives, acceptable acid addition salts. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by endothelin receptor antagonists, particularly those diseases and conditions that are beneficially treated by selective inhibitors of endothelin type-A receptors.
本发明涉及一种新型内皮素受体拮抗剂,其选择性地抑制内皮素-1(ET-1)与内皮素A型受体之间的相互作用,以及其衍生物和可接受的酸盐。本发明还提供了包含本发明化合物的组合物,并将这些组合物用于治疗有益于内皮素受体拮抗剂治疗的疾病和病况,特别是那些有益于内皮素A型受体选择性抑制剂治疗的疾病和病况。